| Journal | Neurogastroenterology and motility |
| Study Type | Cohort |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Cyclical Vomiting Syndrome (CVS) poses a significant financial burden on the healthcare system due to frequent emergency department (ED) visits and hospitalizations. Data on the impact of cannabis use in CVS is conflicting. This study evaluates the impact of cannabis use on outcomes in individuals with CVS using real-world data. A retrospective cohort study was conducted using the TriNetX research network to identify adults (≥ 18 years) with CVS. Patients were categorized into two groups: CVS with cannabis use and CVS without cannabis use (controls). Using propensity score matching on demographics, body mass index, comorbidities and treatments (e.g., abortive and prophylactic therapy) cohorts were matched 1:1. Outcomes included all-cause ED visits and hospitalizations. A total of 18,588 individuals with CVS and cannabis use were matched with 18,588 individuals with CVS who did not use cannabis (controls). Cannabis users were younger (mean age [SD]: 31.9 [12.5] vs. 39.0 [19.9] years) an
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Why study cannabis use in people with cyclical vomiting syndrome?
Cyclical vomiting syndrome places a significant financial burden on the healthcare system because of frequent emergency department visits and hospitalizations, and existing data on how cannabis use affects the condition are conflicting. This study set out to evaluate the impact of cannabis use on outcomes in people with CVS using real-world data.
What kind of study was this, and what outcomes did it track?
It was a retrospective cohort study using real-world data from the TriNetX research network to identify adults aged 18 and older with cyclical vomiting syndrome. Patients were split into those who used cannabis and those who did not, and the outcomes compared were all-cause emergency department visits and hospitalizations.
How did researchers make the cannabis and non-cannabis groups comparable?
They used propensity score matching, pairing patients 1:1 on demographics, body mass index, comorbidities and treatments, such as abortive and prophylactic therapy. The control group consisted of adults with cyclical vomiting syndrome who did not use cannabis.
How many patients were included in the matched analysis?
The study matched 18,588 people with cyclical vomiting syndrome who used cannabis with 18,588 people with the condition who did not use cannabis. The article also reports that the cannabis users were younger, with a mean age of 31.9 years compared with 39.0 years.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
